238 related articles for article (PubMed ID: 36048538)
41. Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
Liu C; Shaurova T; Shoemaker S; Petkovich M; Hershberger PA; Wu Y
Mol Pharm; 2018 Aug; 15(8):3216-3226. PubMed ID: 29902012
[TBL] [Abstract][Full Text] [Related]
42. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.
Kim J; Vasu VT; Mishra R; Singleton KR; Yoo M; Leach SM; Farias-Hesson E; Mason RJ; Kang J; Ramamoorthy P; Kern JA; Heasley LE; Finigan JH; Tan AC
Bioinformatics; 2014 Sep; 30(17):2393-8. PubMed ID: 24812339
[TBL] [Abstract][Full Text] [Related]
43. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
44. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
45. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.
Johnson M; Garassino MC; Mok T; Mitsudomi T
Lung Cancer; 2022 Aug; 170():41-51. PubMed ID: 35714425
[TBL] [Abstract][Full Text] [Related]
46. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
[TBL] [Abstract][Full Text] [Related]
47. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
Yang YM; Jang Y; Lee SH; Kang B; Lim SM
Lung Cancer; 2020 Aug; 146():70-77. PubMed ID: 32521387
[TBL] [Abstract][Full Text] [Related]
48. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
Kim WY; Prudkin L; Feng L; Kim ES; Hennessy B; Lee JS; Lee JJ; Glisson B; Lippman SM; Wistuba II; Hong WK; Lee HY
Cancer; 2012 Aug; 118(16):3993-4003. PubMed ID: 22359227
[TBL] [Abstract][Full Text] [Related]
49. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
50. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
Cardona AF; Ruiz-Patiño A; Recondo G; Martín C; Raez L; Samtani S; Minata JN; Blaquier JB; Enrico D; Burotto M; Ordóñez-Reyes C; Chamorro DF; Garcia-Robledo JE; Corrales L; Zatarain-Barrón ZL; Más L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Rodríguez J; Archila P; Bermudez M; Gamez T; Cordeiro de Lima V; Freitas H; Russo A; Polo C; Malapelle U; Perez DM; Rolfo C; Viola L; Rosell R; Arrieta O
Clin Lung Cancer; 2022 Sep; 23(6):522-531. PubMed ID: 35798634
[TBL] [Abstract][Full Text] [Related]
51. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
52. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
[TBL] [Abstract][Full Text] [Related]
53. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
54. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR
Yin W; Zhao Y; Kang X; Zhao P; Fu X; Mo X; Wang Y; Huang Y
Theranostics; 2020; 10(14):6122-6135. PubMed ID: 32483443
[TBL] [Abstract][Full Text] [Related]
55. Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.
Lee PC; Fang YF; Yamaguchi H; Wang WJ; Chen TC; Hong X; Ke B; Xia W; Wei Y; Zha Z; Wang Y; Kuo HP; Wang CW; Tu CY; Chen CH; Huang WC; Chiang SF; Nie L; Hou J; Chen CT; Huo L; Yang WH; Deng R; Nakai K; Hsu YH; Chang SS; Chiu TJ; Tang J; Zhang R; Wang L; Fang B; Chen T; Wong KK; Hsu JL; Hung MC
Cancer Cell; 2018 Dec; 34(6):954-969.e4. PubMed ID: 30537515
[TBL] [Abstract][Full Text] [Related]
56. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
57. FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.
Niu M; Xu J; Liu Y; Li Y; He T; Ding L; He Y; Yi Y; Li F; Guo R; Gao Y; Li R; Li L; Fu M; Hu Q; Luo Y; Zhang C; Qin K; Yi J; Yu S; Yang J; Chen H; Wang L; Li Z; Dong B; Qi S; Ouyang L; Zhang Y; Cao Y; Xiao ZJ
Nat Commun; 2021 Oct; 12(1):5919. PubMed ID: 34635651
[TBL] [Abstract][Full Text] [Related]
58. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
59. R2-8018 reduces the proliferation and migration of non-small cell lung cancer cells by disturbing transactivation between M3R and EGFR.
Lan L; Wang H; Yang R; Liu F; Bi Q; Wang S; Wei X; Yan H; Su R
Life Sci; 2019 Oct; 234():116742. PubMed ID: 31401315
[TBL] [Abstract][Full Text] [Related]
60. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
Liu B; Chen D; Chen S; Saber A; Haisma H
Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
